6-(2-chloro-5-((2S,3S,4R,5R,6R)-3,4,5-tris(benzyloxy)-6-(benzyloxymethyl)tetrahydro-2H-pyran-2-yl)benzyl)pyridazine-3-carbonitrile | 1234347-90-0

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 6-(2-chloro-5-((2S,3S,4R,5R,6R)-3,4,5-tris(benzyloxy)-6-(benzyloxymethyl)tetrahydro-2H-pyran-2-yl)benzyl)pyridazine-3-carbonitrile
• 英文别名: 6-(2-Chloro-5-((2S,3S,4R,5R,6R)-3,4,5-tris(benzyloxy)-6-(benzyloxymethyl)-tetrahydro-2H-pyran-2-yl)benzyl)pyridazine-3-carbonitrile；6-[[2-chloro-5-[(2S,3S,4R,5R,6R)-3,4,5-tris(phenylmethoxy)-6-(phenylmethoxymethyl)oxan-2-yl]phenyl]methyl]pyridazine-3-carbonitrile
• CAS: 1234347-90-0
• 化学式: C₄₆H₄₂ClN₃O₅
• 分子量: 752.31
• InChiKey: IOJFVLGJATWHLA-GYNXGUMWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.6
• 重原子数：
  55
• 可旋转键数：
  16
• 环数：
  7.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  95.7
• 氢给体数：
  0
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  6-(2-chloro-5-((2S,3S,4R,5R,6R)-3,4,5-tris(benzyloxy)-6-(benzyloxymethyl)tetrahydro-2H-pyran-2-yl)benzyl)pyridazine-3-carbonitrile 在 水 、 sodium hydroxide 、 盐酸 作用下， 以 乙醇 、 水 为溶剂， 生成 6-(2-chloro-5-((2S,3S,4R,5R,6R)-3,4,5-tris(benzyloxy)-6-(benzyloxymethyl)tetrahydro-2H-pyran-2-yl)benzyl)pyridazine-3-carboxylic acid
  参考文献：
  名称：

  [EN] NOVEL C-ARYL GLUCOSIDE SGLT2 INHIBITORS AND PHARMACEUTICAL COMPOSITION COMPRISING SAME
  [FR] NOUVEAUX INHIBITEURS DE SGLT2 CONSISTANT EN C-ARYL GLUCOSIDES ET COMPOSITION PHARMACEUTIQUE LES COMPRENANT

  摘要：

  公开号：

  WO2010147430A3
• 作为产物：
  描述：

  zinc(II) cyanide 、 3-chloro-6-(2-chloro-5-((2S,3S,4R,5R,6R)-3,4,5-tris(benzyloxy)-6-(benzyloxymethyl)tetrahydro-2H-pyran-2-yl)benzyl)pyridazine 在 四(三苯基膦)钯 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 0.25h， 以52%的产率得到6-(2-chloro-5-((2S,3S,4R,5R,6R)-3,4,5-tris(benzyloxy)-6-(benzyloxymethyl)tetrahydro-2H-pyran-2-yl)benzyl)pyridazine-3-carbonitrile
  参考文献：
  名称：

  [EN] NOVEL C-ARYL GLUCOSIDE SGLT2 INHIBITORS AND PHARMACEUTICAL COMPOSITION COMPRISING SAME
  [FR] NOUVEAUX INHIBITEURS DE SGLT2 CONSISTANT EN C-ARYL GLUCOSIDES ET COMPOSITION PHARMACEUTIQUE LES COMPRENANT

  摘要：

  公开号：

  WO2010147430A3

文献信息

• NOVEL C-ARYL GLUCOSIDE SGLT2 INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME
  申请人：Lee Jinhwa

  公开号：US20120101051A1

  公开（公告）日：2012-04-26

  A novel C-aryl glucoside compound, or a pharmaceutically acceptable salt or a prodrug thereof having an inhibitory activity against sodium-dependent glucose cotransporter 2 (SGLT2) being present in the intestine and kidney; and a pharmaceutical composition comprising the same as an active ingredient, which is useful for preventing or treating metabolic disorders, particularly, diabetes, are provided.

  提供了一种新型的C-芳基葡萄糖苷化合物，或其药学上可接受的盐或前药，具有抑制肠道和肾脏中存在的钠依赖性葡萄糖共转运体2（SGLT2）的活性；以及包含该化合物作为活性成分的制药组合物，可用于预防或治疗代谢性疾病，特别是糖尿病。
• C-aryl glucoside SGLT2 inhibitors and pharmaceutical compositions comprising same
  申请人：Lee Jinhwa

  公开号：US08541380B2

  公开（公告）日：2013-09-24

  A novel C-aryl glucoside compound, or a pharmaceutically acceptable salt or a prodrug thereof having an inhibitory activity against sodium-dependent glucose cotransporter 2 (SGLT2) being present in the intestine and kidney; and a pharmaceutical composition comprising the same as an active ingredient, which is useful for preventing or treating metabolic disorders, particularly, diabetes, are provided.

  提供一种新的C-芳基葡萄糖苷化合物，或其药物可接受的盐或前药，具有对存在于肠和肾中的钠依赖性葡萄糖共转运体2（SGLT2）的抑制活性；以及包含其作为活性成分的制药组合物，该组合物对预防或治疗代谢紊乱特别是糖尿病有用。
• Novel C-aryl glucoside SGLT2 inhibitors as potential antidiabetic agents: Pyridazinylmethylphenyl glucoside congeners
  作者：Min Ju Kim、Junwon Lee、Suk Youn Kang、Sung-Han Lee、Eun-Jung Son、Myung Eun Jung、Suk Ho Lee、Kwang-Seop Song、MinWoo Lee、Ho-Kyun Han、Jeongmin Kim、Jinhwa Lee

  DOI：10.1016/j.bmcl.2010.04.006

  日期：2010.6

  Novel C-aryl glucoside SGLT2 inhibitors containing pyridazine motif were designed and synthesized for biological evaluation. Among the compounds tested, pyridazine containing methylthio moiety 22l or thiadiazole ring 22ah showed the best in vitro inhibitory activities in this series (IC50 = 13.4, 11.4 nM, respectively) against SGLT2 to date. Subsequently, compound 22l exhibited reasonable urinary glucose excretion and glucosuria in normal SD rats, thereby demonstrating that this pyridazine series possesses both in vitro SGLT2 inhibition and in vivo efficacy, albeit to a lower degree. (C) 2010 Elsevier Ltd. All rights reserved.
• US8541380B2
  申请人：——

  公开号：US8541380B2

  公开（公告）日：2013-09-24
• [EN] NOVEL C-ARYL GLUCOSIDE SGLT2 INHIBITORS AND PHARMACEUTICAL COMPOSITION COMPRISING SAME<br/>[FR] NOUVEAUX INHIBITEURS DE SGLT2 CONSISTANT EN C-ARYL GLUCOSIDES ET COMPOSITION PHARMACEUTIQUE LES COMPRENANT
  申请人：GREEN CROSS CORP

  公开号：WO2010147430A3

  公开（公告）日：2011-05-05